Psych drug usage way up in U.S.; Elan surges on new Lundbeck gossip;

> Some 73 percent more American adults are taking psych meds now than in 1996, as primary-care doctors have grown more familiar with the drugs and insurers expanded coverage. Report

> Shares in Irish pharmaceutical company Elan rose by as much as 17 percent in Dublin this morning on renewed market speculation that Danish drugmaker Lundbeck will make a bid. Report

> Johnson & Johnson has reclaimed the top spot in the 10th Annual Harris Interactive Quotient Study, marking it as having the best reputation of the 60 most visible companies in the U.S. Release

> McKesson reported an 8 percent drop in fiscal fourth-quarter earnings and flat revenue, and the drug distributor gave a guarded outlook for the current year. Report

> Aeras Global TB Vaccine Foundation celebrated the opening of its new tuberculosis vaccine manufacturing plant, expected to create 25 new bioscience jobs in Rockville, Md. Report

> Cipla got the FDA's tentative nod for its version of Gilead Sciences' HIV med Truvada; the approval comes under the President's Emergency Plan for AIDS Relief. Report

> Merck Serono launched its powder formulation of the diabetes med Glucophage in France and the U.K., hoping to broaden coverage in Europe later this year. Merck release

> Australia's Pharmaxis says that Bronchitol, its experimental cystic-fibrosis drug, met its primary and secondary goal in a late-stage study. Report

> Genetic Engineering & Biotech News has identified Brazil, China and India as three of the world's leading countries actively engineering the development of key biotech clusters that could rival Boston, San Francisco and San Diego. Report

> It turns out that biotech's loss will be academia's gain. Genentech's Susan Desmond-Hellmann, who reaped a rich reward from the Roche deal, is to become chancellor of UC San Francisco. Report

> Virologists have been working around the clock to gain a better understanding of the A/H1N1 flu virus. Report

> Acadia Pharmaceuticals will pocket $30 million upfront and stands to earn another $365 million in milestones from Biovail as they pursue an approval for a late-stage drug designed to treat Parkinson's disease psychosis. Report

> As the Burnham Institute for Medical Research in Florida moves from temporary digs into a new, 178,000-square-foot facility, its top scientists have been stepping up their recruitment of fresh talent. Report

> The Los Angeles Times followed the swine flu from its identification in San Diego to the level 5 pandemic alert that it triggered in a matter of days. Report

> In a report for the Annals of Internal Medicine, Steven Woloshin and Lisa Schwartz say that close to a third of all the releases put out by academic research centers or their affiliates hyped researchers' findings. Report

And Finally... Academic medical centers sometimes hype their research results to get press, a new study finds. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.